First-line sunitinib for metastatic renal cell carcinoma, a 15-year single institution real-world evidence study

When compared to other RWEs, our PFS and OS for all patients fell within the spectrum of previously published results. IMDC risk group was identified as the most significant factor for PFS and OS. PFS and OS for IMDC favorable-risk patients were among the highest reported in existing RWE studies. Importantly, we found sunitinib monotherapy to be an effective treatment in IMDC favorable-risk patients, comparable to published IO-TKI results, supporting its use, especially seen in relation to price.